
July 1 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O:
VERRICA PHARMACEUTICALS ANNOUNCES AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH TORII PHARMACEUTICAL TO LAUNCH GLOBAL PIVOTAL PHASE 3 CLINICAL TRIAL TO STUDY YCANTH® FOR THE TREATMENT OF COMMON WARTS
VERRICA PHARMACEUTICALS INC - TO RECEIVE $8 MILLION MILESTONE PAYMENT IN JULY 2025
VERRICA PHARMACEUTICALS INC - TO RECEIVE $10 MILLION MILESTONE PAYMENT UPON YCANTH APPROVAL IN JAPAN
VERRICA PHARMACEUTICALS INC - TORII TO FUND FIRST $40 MILLION OF GLOBAL STUDY COSTS